A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to characterize the pharmacokinetics and tolerability of buprenorphine patches in children who require opioid pain relief for moderate to severe mouth pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain

NCT01324544

Other Acute Postoperative Pain Prolonged Endotracheal Intubation

WITHDRAWN PHASE3

Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children

NCT01324570

Pain

COMPLETED PHASE3

Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain

NCT00941304

Dental Pain

COMPLETED PHASE2

Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure

NCT03608696

Neonatal Abstinence Syndrome Neonatal Opiate Withdrawal Syndrome

COMPLETED PHASE1/PHASE2

Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients

NCT01841931

Opioid Use Disorder

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will be screened for eligibility and if eligible will apply a buprenorphine patch (Day 1). The patch will be worn for 7 days during which time, safety assessments, pain scores, mucositis scores, PK sampling \& vital signs will be assessed on each day. After patch removal subjects will continue with these assessments on a daily basis until Day 12. The subject will then be followed up for 10 days (to Day 22) to collect information on ongoing/new SAEs/AEs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chemotherapy Induced Mucositis Mouth Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patch

Group Type EXPERIMENTAL

Buprenorphine

Intervention Type DRUG

Transdermal patch

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Buprenorphine

Transdermal patch

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female children experiencing severe mouth pain secondary to chemotherapy induced mucositis requiring opioid analgesic therapy and who will be an inpatient, as a minimum up to Day 8 (patch removal).
2. Subjects experiencing 'severe' pain in the Investigators clinical judgment.
3. Body weight ≥ 15 kg. Subjects weighing ≥ 25 kg will be recruited in the first phase of the study with those weighing \< 25 kg also being included in the second phase, (after a successful review by an IDSMC). Upper age range to be 16 years.
4. In dwelling IV cannula or central line from which blood can be obtained.
5. Written informed consent obtained from parent(s)/legal representative, and where possible assent obtained from the subject if appropriate, in line with local regulations.
6. Females of child bearing potential must have a negative urine pregnancy test if the Principal Investigator considers there to be a reasonable possibility of pregnancy.

Exclusion Criteria

1. Subjects with known hypersensitivity to buprenorphine or any of its excipients in the transdermal system, as outlined in the Summary of Product Characteristics for BuTrans.
2. Known hypersensitivity to other opioids.
3. Skin disease affecting application or local tolerance of BTDS.
4. Clinically significant history of allergic reaction to wound dressings or adhesives.
5. Severe respiratory impairment.
6. Clinically significant hepatic dysfunction.
7. Severe renal impairment.
8. Subjects who are receiving MAO inhibitors or have taken them within the previous 2 weeks.
9. Subjects receiving hypnotics or other central nervous system (CNS) depressants that, in the investigator's opinion, may pose a risk of additional CNS depression with study medication.
10. Subjects who have taken any buprenorphine preparations in the last 14 days.
11. Subjects with myasthenia gravis.
12. Subjects with convulsive disorders, head injury, shock, or reduced level of consciousness of uncertain origin.
13. Subjects who are currently participating in another clinical research study involving a new chemical entity (NCE) unless the sole purpose of the other trial at the time of BUP1501 screening is for long term follow-up/survival data or subjects who have participated in a clinical study within the previous 30 days. Participation in a chemotherapy clinical trial that is not evaluating a NCE will be accepted for inclusion.
14. Subjects who are pregnant, lactating or in the Investigators opinion are at risk of conceiving.
15. Previous enrollment in this clinical study.
16. Subjects who the Investigator believes are unsuitable for the study.

Minimum Eligible Age

2 Years

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No